本文選題：補腎平喘方 + 哮喘�。� 參考：《蚌埠醫(yī)學院》2014年碩士論文

【摘要】：目的： 通過觀察補腎平喘方（Bushen Pingchuan Prescription）對大鼠哮喘模型的防治作用，初步探討本方抗哮喘的作用及作用機制，為該處方的進一步開發(fā)提供初步的實驗依據(jù)。 方法： SPF級清潔雄性SD大鼠60只，采用腹腔注射卵蛋白（OVA）與氫氧化鋁致敏、OVA霧化吸入激發(fā)來復制哮喘動物模型。第1，7天除空白對照組外，其余大鼠腹腔注射卵蛋白（OVA）與氫氧化鋁致敏，之后將其隨機分為5組：模型組（等容量蒸餾水）、補腎防喘片組(6.21g/kg)、補腎平喘方高劑量組(49.68g/kg)、補腎平喘方中劑量組(24.84g/kg)、補腎平喘方低劑量組(12.42g/kg)，每組10只。第15天起每天霧化激發(fā)，于激發(fā)前半小時各給藥組給藥。第1,2周霧化濃度為1％，第3,4周為1.5％，第5,6周為2％，第7,8周為2.5％。 于末次給藥激發(fā)后，禁食24h，麻醉、取血、取大鼠肺臟；測定肺臟重量、肺臟指數(shù)，分離取血清及血漿,采用ELISA法檢測血清中IL-4，IFN-γ，IgE，CORT的含量及血漿中ACTH的含量。將肺組織放入10％的甲醛里浸泡，待進行HE染色，在光學顯微鏡下觀察大鼠肺組織形態(tài)結構，自動成像系統(tǒng)拍攝圖片。免疫組化法檢測肺組織內(nèi)β-AR的含量。 結果： 1.補腎平喘方通過補腎溫陽、宣肺降氣，改善大鼠腎虛哮喘癥狀如精神萎靡、喘息、咳嗽等。 2.補腎平喘方能顯著降低大鼠肺臟指數(shù)，與模型空白組相比有顯著差異性（P㩳0.01），其中補腎平喘方中劑量組效果明顯。 3.補腎平喘方能顯著改善哮喘肺組織病理水平，與模型空白組相比具有顯著性差異。 4.補腎平喘方能顯著降低血清IL-4同時升高血清IFN-γ的水平，與模型對照組相比有顯著差異性（P㩳0.05、P㩳0.01），抑制Th2細胞的優(yōu)勢表達，調(diào)節(jié)哮喘炎性反應。 5.補腎平喘方顯著降低大鼠血清中IgE的水平，，與模型對照組相比有顯著差異性（P㩳0.05、P㩳0.01）。 6.補腎平喘方能顯著降低大鼠血清CORT，血漿ACTH的水平，調(diào)節(jié)HPA軸的功能，與模型對照組相比，差異具有顯著性（P㩳0.01、P㩳0.05）。 7.補腎平喘方能提高大鼠肺組織中β-AR的水平，與模型對照組相比具有顯著性差異（P㩳0.05、P㩳0.01）。 結論： 1.哮喘模型組大鼠肺臟病理形態(tài)顯著病變，血清中IL-4升高、IFN-γ降低，IgE顯著提高，同時大鼠出現(xiàn)一系列的腎虛癥狀精神萎靡、喘息、咳嗽等，證明采用卵蛋白加氫氧化鋁注射致敏并給予霧化激發(fā)可以成功復制哮喘動物模型。 2.補腎平喘方降低大鼠肺臟指數(shù)、血清IL-4與IgE，同時升高IFN-γ水平，可能與抑制Th2細胞的優(yōu)勢表達，調(diào)節(jié)Th1與Th2的平衡有關。 3.補腎平喘方能升高CORT，ACTH的表達，減輕肺組織病變程度，可能與調(diào)節(jié)HPA軸的平衡有關，即通過下丘腦-腺垂體-腎上腺軸來調(diào)節(jié)糖皮質(zhì)激素的水平，發(fā)揮免疫抑制及抗炎作用；此外還提高了 AR的水平，通過擴張支氣管及擴張血管等作用來減緩哮喘癥狀。 4.補腎平喘方溫補腎陽、宣肺降逆，對哮喘模型大鼠具有一定的防治作用。
[Abstract]:Objective: By observing the preventive and therapeutic effects of Bushen Pingchuan Prescription( Bushen Pingchuan Prescription) on asthma in rats, the effect and mechanism of Bushen Pingchuan Prescriptionof Bushen on asthma in rats were preliminarily discussed, which provided a preliminary experimental basis for the further development of this prescription. Methods: 60 SPF grade clean male SD rats were injected intraperitoneally with ovalbumin and aluminum hydroxide to induce asthma model. On the 1st day of 7 days, the other rats were sensitized with aluminum hydroxide by intraperitoneal injection of ovalbumin OVA, except for the blank control group. Then it was randomly divided into five groups: model group (equal volume distilled water, Bushen anti-asthma tablet group, 6.21 g / kg 路kg ~ (-1), high dose group (49.68 g / kg 路kg ~ (-1), medium dose group (24.84 g / kg) and low dose group (12.42 g / kg 路kg ~ (-1), 10 rats in each group. Every day after 15 days of atomization, each group was administered half an hour before excitation. The atomization concentration was 1 at week 1, 1.5 at week 3, 2 at week 5 and 2 at week 7, and 2. 5 at week 7. The lung weight, lung index, serum and plasma levels of IL-4, IFN- 緯, IgECORT and ACTH in plasma were determined by ELISA method. The lung tissue was immersed in 10% formaldehyde for HE staining. The morphologic structure of lung tissue was observed under optical microscope and the images were taken by automatic imaging system. The content of 尾-AR in lung tissue was detected by immunohistochemical method. Results: 1. Bushen Pingchuan prescription can improve asthmatic symptoms of kidney deficiency such as depression, wheezing and coughing by tonifying kidney and warming yang, promoting lung and reducing qi. 2. Bushen Pingchuan recipe can significantly reduce the lung index of rats, compared with the model blank group, there is a significant difference between the P0. 01, among which the effect of Bushen Pingchuan decoction medium dose group is obvious. 3. Bushen Pingchuan recipe can significantly improve the lung pathological level of asthma compared with the model blank group has a significant difference. 4. Bushen Pingchuan recipe could significantly reduce serum IL-4 and increase the level of serum IFN- 緯. Compared with the model control group, there was a significant difference between the two groups. Compared with the model control group, Bushen Pingchuan recipe could inhibit the predominant expression of Th2 cells and regulate the inflammatory response of asthma. 5. Bushen Pingchuan recipe significantly decreased the level of IgE in serum of rats, and there was significant difference compared with the model control group. 6. Bushen Pingchuan recipe could significantly reduce the level of Cort, plasma ACTH and regulate the function of HPA axis in rats. Compared with the model control group, the difference was significant. 7. Bushen Pingchuan recipe could increase the level of 尾 -AR in lung tissue of rats, and had significant difference compared with the model control group. Conclusion: 1. In the asthmatic model group, the pathological changes of lung were significant, the serum level of IFN- 緯 was significantly increased, and a series of symptoms of kidney deficiency, such as depression, wheezing and coughing, were found in the rats. It was proved that the asthmatic animal model could be successfully induced by injection of ovalbumin and aluminum hydroxide. 2. The decrease of lung index, serum IL-4 and IgE, and the increase of IFN- 緯 level may be related to the inhibition of the dominant expression of Th2 cells and the regulation of the balance between Th1 and Th2. 3. Bushen Pingchuan prescription can increase the expression of Corton-ACTH and reduce the degree of lung pathological changes, which may be related to regulating the balance of HPA axis, that is, regulating the level of glucocorticoid through hypothalamus-pituitary-adrenal axis, and exerting immunosuppressive and anti-inflammatory effects. It also improves the level of AR and relieves asthma symptoms by dilating bronchi and dilating blood vessels. 4. The prescription of tonifying kidney and relieving asthma has preventive and therapeutic effect on asthmatic rats.
【學位授予單位】：蚌埠醫(yī)學院
【學位級別】：碩士
【學位授予年份】：2014
【分類號】：R259

【參考文獻】

相關期刊論文 前10條

1 彭波;童佳兵;王傳博;楊程;張四春;李澤庚;;中醫(yī)肺系疾病古籍文獻的整理及數(shù)據(jù)庫的建立[J];安徽中醫(yī)學院學報;2010年01期

2 李新;;益氣固肺疏風法治療支氣管哮喘臨床緩解期30例療效觀察[J];北京中醫(yī)藥;2011年04期

3 趙志旭;馮學斌;李營營;吳福玲;楊成;;支氣管哮喘大鼠淋巴液CD4~+CD25~+Treg及其Th1/Th2失衡的實驗研究[J];濱州醫(yī)學院學報;2010年01期

4 鐘代華;張莉;王天文;蔣渝;;補腎防喘片的藥效學及急性毒性研究[J];重慶中草藥研究;2002年01期

5 張智娟;黃美杏;陳學遠;梁愛武;;補腎防哮湯治療支氣管哮喘慢性持續(xù)期20例臨床觀察[J];廣西中醫(yī)藥;2009年01期

6 郭武;;蘇陳九寶湯、補腎地黃湯合西藥治療小兒哮喘近期療效觀察[J];廣西中醫(yī)藥;2010年05期

7 王嬌;熊瑛;熊彬;王宋平;;麻黃水提物霧化吸入對哮喘小鼠氣道炎癥的影響[J];重慶醫(yī)學;2013年03期

8 朱慧華;劉俊方;虞堅爾;;支氣管哮喘中醫(yī)證候現(xiàn)代研究進展[J];甘肅中醫(yī)學院學報;2013年01期

9 馮艷青;彭勛;趙培利;;建立支氣管哮喘大鼠模型的新方法及評價[J];河北醫(yī)藥;2011年24期

10 呂海寧;張克誠;崔增杰;折改梅;;核桃青皮體外抑菌活性的研究[J];華西藥學雜志;2011年02期

相關博士學位論文 前2條

1 蘇奎國;五紫三黃方對激素依賴性哮喘小鼠模型作用機理的實驗研究[D];北京中醫(yī)藥大學;2012年

2 許珂玉;補脾益氣方藥對哮喘大鼠治療機制的研究[D];遼寧中醫(yī)藥大學;2012年

本文編號：1902665